Teknova reports third quarter 2023 financial results

Raised $22.9 million of equity capital, paid down $10.0 million of long-term debt third quarter 2023 total revenue was $8.2 million, down 24% from prior year expect 2023 revenue at the low end of previously announced guidance range of $37-40 million hollister, calif., nov. 09, 2023 (globe newswire) -- alpha teknova, inc. (“teknova” or the “company”) (nasdaq: tkno), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the third quarter ended september 30, 2023.
TKNO Ratings Summary
TKNO Quant Ranking